MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Search

Merit Medical Systems Inc

Atvērts

SektorsVeselības aprūpe

83.2 0.68

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

81.99

Max

83.86

Galvenie mērījumi

By Trading Economics

Ienākumi

-4.8M

28M

Pārdošana

1.7M

384M

P/E

Sektora vidējais

42.21

89.037

Peļņas marža

7.225

Darbinieki

7,400

EBITDA

-4.4M

80M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+28.68% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 24. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-20M

4.9B

Iepriekšējā atvēršanas cena

82.52

Iepriekšējā slēgšanas cena

83.2

Ziņu noskaņojums

By Acuity

50%

50%

177 / 360 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

Merit Medical Systems Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 21. janv. 23:49 UTC

Galvenie tirgus virzītāji

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

2026. g. 21. janv. 21:12 UTC

Galvenie tirgus virzītāji

Automaker Stocks Rise After Trump Calls Off European Tariffs

2026. g. 21. janv. 21:00 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

2026. g. 21. janv. 20:29 UTC

Galvenie tirgus virzītāji

Chip Makers Gain After Trump Calls Off European Tariffs

2026. g. 21. janv. 20:04 UTC

Galvenie tirgus virzītāji

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

2026. g. 21. janv. 23:48 UTC

Tirgus saruna

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

2026. g. 21. janv. 23:34 UTC

Tirgus saruna

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

2026. g. 21. janv. 22:39 UTC

Peļņas

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

2026. g. 21. janv. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 21. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 21. janv. 21:35 UTC

Iegādes, apvienošanās, pārņemšana

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

2026. g. 21. janv. 21:19 UTC

Peļņas

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

2026. g. 21. janv. 20:45 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Borse Group to Acquire Allfunds for $6.19B

2026. g. 21. janv. 20:36 UTC

Tirgus saruna

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

2026. g. 21. janv. 20:31 UTC

Tirgus saruna

Oil Settles Higher With Support From Heating Fuel -- Market Talk

2026. g. 21. janv. 20:27 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

2026. g. 21. janv. 20:27 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 21. janv. 20:27 UTC

Tirgus saruna

Was It a 'TACO' Event? -- Market Talk

2026. g. 21. janv. 20:26 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

2026. g. 21. janv. 20:23 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

2026. g. 21. janv. 20:21 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

2026. g. 21. janv. 20:19 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse Group Agrees to Buy Allfunds

2026. g. 21. janv. 20:08 UTC

Peļņas

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

2026. g. 21. janv. 20:03 UTC

Tirgus saruna

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

2026. g. 21. janv. 19:51 UTC

Tirgus saruna

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

2026. g. 21. janv. 19:43 UTC

Tirgus saruna

U.S. Ethanol Production Expected to Slip -- Market Talk

2026. g. 21. janv. 19:31 UTC

Tirgus saruna

Gold Settles at Fresh All-Time High -- Market Talk

2026. g. 21. janv. 19:24 UTC

Peļņas

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

2026. g. 21. janv. 19:10 UTC

Tirgus saruna

Mexican Inflation Seen Picking Up in Early January -- Market Talk

2026. g. 21. janv. 18:57 UTC

Tirgus saruna

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Salīdzinājums

Cenas izmaiņa

Merit Medical Systems Inc Prognoze

Cenas mērķis

By TipRanks

28.68% augšup

Prognoze 12 mēnešiem

Vidējais 105.13 USD  28.68%

Augstākais 122 USD

Zemākais 90 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Merit Medical Systems Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

7

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

95.585 / 96.35Atbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

177 / 360 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Merit Medical Systems Inc

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate structures; gastroenterology products, such as covered esophageal stents, syringe and gauges, and balloon dilators; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
help-icon Live chat